Atossa’s progress reflects the strong strategic momentum promised in the March 11, 2025 announcement of a metastatic focus; momentum that aligns well with FDA expectations and regulatory standards, ...

Vinay Prasad, the U.S. Food and Drug Administration's chief medical and science officer, has left the health regulator, the U ...

Improving how the FDA disseminates already-public information about approved drugs may be unsexy, but it would be a big step ...

Vinay Prasad, the U.S. Food and Drug Administration's chief medical and science officer, has left the health regulator, STAT ...